Shanghai Henlius Biotech Dividendos y recompras

Dividendo controles de criterios 0/6

Shanghai Henlius Biotech no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Rendimiento de la recompra

Rendimiento total para el accionista	n/a
Rendimiento futuro de los dividendos	0%
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de 2696 han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de 2696 han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Shanghai Henlius Biotech vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de 2696 con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (2696)	n/a
Suelo de mercado 25% (HK)	3.3%
Techo de mercado 25% (HK)	8.0%
Media de la industria (Biotechs)	1.2%
Analista de previsiones (2696) (hasta 3 años)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de 2696 en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de 2696 en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de 2696 para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que 2696 no ha comunicado ningún pago.

Descubre empresas que pagan buenos dividendos

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/01/30 23:20
Precio de las acciones al final del día	2025/01/28 00:00
Beneficios	2024/06/30
Ingresos anuales	2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

Shanghai Henlius Biotech, Inc. está cubierta por 14 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Yang Huang	BofA Global Research
Wangbin Zhou	Citigroup Inc
Eva Zhao	Citigroup Inc

Shanghai Henlius Biotech Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Investor sentiment deteriorates as stock falls 17%

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Phase 1B/2 Clinical Trial of Hlx43 for Injection (Antibody-Drug Conjugate Targetingpd-L1 with Novel Dna Topoisomerase I Inhibitor) in Combination with Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient in Mainland China Dosed in an International Multi-Center Phase 3 Clinical Study

New major risk - Revenue and earnings growth

Shanghai Henlius Biotech Announces Application for the Phase 1b/2 Clinical Trial of HLX43 for Injection Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication of Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC)

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Receives Positive Opinion from the Committee Formedicinal Products for Human Use (Chmp)Of the European Medicines Agency (Ema)

Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of Pembrolizumab Biosimilar HLX17 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection)

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Announces Company Secretary Changes

Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024

Shanghai Henlius Biotech, Inc. Announces the First Patient Dose in A Phase 2 Clinical Trial of HLX53

Shanghai Henlius Biotech, Inc. Announces International Multicentre Phase 3 Clinical Trial for the First-Line Treatment of Metastatic Colorectal Cancer in Japan

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02

Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd)

Shanghai Henlius Biotech, Inc. Announces the Phase 1b/2 Clinical Trial of Hlx07